Abstract
About 20% of breast cancer patients overexpress the Human Epidermal growth factor Receptor-2 (HER2), also known as ErbB2. HER2-overexpression is associated with enhanced tumor malignancy and its overexpression is related to specific target therapy against breast tumors and other cancers. HER2-mediated pathways in tumor cells act on behalf of the tumor conferring aggressive characteristics. Several reports demonstrated the occurrence of toxicity during the anti-HER2 therapy and this fact has been associated with the generation of reactive species and oxidative stress. However, the link between HER2 and oxidative stress signaling is still poorly understood. The aim of this review is to point out the interplay between oxidative stress and HER2 signaling in breast cancer. An overview regarding HER2 biology and oxidative stress pathways is provided with a special focus in studies that implicate on HER2-generation of reactive species and oxidative stress during trastuzumab-based treatments.
Highlights
Breast cancer is the most lethal malignancy in women worldwide, with the highest incidence in both developed and developing countries (WHO, 2014)
Tumors were identified into four different groups: Luminal A and B, triple negative and HER2overexpressed (Sioshansi et al, 2011)
Reactive species and antioxidants mediate important cell signaling pathways that are overactive in cells with Human Epidermal growth factor Receptor-2 (HER2) amplification/overexpression
Summary
Breast cancer is the most lethal malignancy in women worldwide, with the highest incidence in both developed and developing countries (WHO, 2014). The development of breast cancer is multifactorial, where environmental and genetic susceptibility may play an important role (Johnson-Thompson and Guthrie, 2000). T0he patterns provided a distinct molecular portrait of each tumor, whose standards reflect a relationship between tumors and connections between a specific gene and specific tumor. According to this classification, tumors were identified into four different groups: Luminal A and B (positive tumors expressing estrogen receptors-ER and progesterone receptors-PR), triple negative ( called basal-like) and HER2overexpressed (human epidermal growth factor 2, known as ErbB2) (Sioshansi et al, 2011)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
